LFS-1107_product_DataBase

Bioactivity	LFS-1107 is a reversible CRM1 inhibitor (Kd: 12.5 pM). LFS-1107 can selectively eliminate extranodal natural killer/T cell lymphoma (ENKTL) cells and can be used for cancer research[1].
Invitro	LFS-1107 (4-9 μM, 72 h) 可选择性清除 ENKT L细胞，同时保留正常人 PBMC ，且在 PBMC 细胞系中具有良好的安全性[1]。LFS-1107 (0.15-500 μM, 24 h) 对人血小板几乎没有影响[1]。LFS-1107 (50-200 nM, 3 h) 可在 293T 细胞中聚集 IκBα[1]。 0 --> LFS-1107 相关抗体: Cell Viability Assay[1] Cell Line:
In Vivo	LFS-1107 (10 mg/kg，腹腔注射，每周1次) 可改善异种移植 SNK6 细胞的小鼠模型的 ENKTL 症状[1]。 Animal Model:
Name	LFS-1107
CAS	1799330-91-8
Formula	C12H11N5OS2
Molar Mass	305.38
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. He Liu, et al. Discovery and biological evaluation of a potent small molecule CRM1 inhibitor for its selective ablation of extranodal NK/T cell lymphoma eLife 12:e80625.

PeptideDB